Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 3/20 | 0.46 |
| ▸ | MVD | P53602 | 2/20 | 0.38 |
| ▸ | GGPS1 | O95749 | 4/20 | 0.38 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.36 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.36 |
| ▸ | FNTA | P49354 | 3/20 | 0.33 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3002864 | 0.98 | BTN3A1 (0.45) | BTN3A1MVDGGPS1LPAR3LPAR1 | |
| SCHEMBL3005196 | 0.98 | BTN3A1 (0.45) | BTN3A1MVDGGPS1LPAR3LPAR1 | |
| SCHEMBL2993317 | 0.98 | BTN3A1 (0.45) | BTN3A1MVDGGPS1LPAR3LPAR1 | |
| SCHEMBL2999226 | 0.98 | BTN3A1 (0.45) | BTN3A1MVDGGPS1LPAR3LPAR1 | |
| SCHEMBL3004732 | 0.98 | BTN3A1 (0.45) | BTN3A1MVDGGPS1LPAR3LPAR1 | |
| SCHEMBL2999121 | 0.98 | BTN3A1 (0.45) | BTN3A1MVDGGPS1LPAR3LPAR1 | |
| SCHEMBL3004918 | 0.98 | BTN3A1 (0.45) | BTN3A1MVDGGPS1LPAR3LPAR1 | |
| SCHEMBL2995236 | 0.98 | BTN3A1 (0.45) | BTN3A1MVDGGPS1LPAR3LPAR1 | |
| SCHEMBL2995155 | 0.98 | BTN3A1 (0.45) | BTN3A1MVDGGPS1LPAR3LPAR1 | |
| SCHEMBL2996806 | 0.98 | BTN3A1 (0.45) | BTN3A1MVDGGPS1LPAR3LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2222647-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | Cephalon, Inc. (US) | 2010-09-01 | — | — | EP | disclosed |
| WO-2010049438-A2 | IMPROVED METHODS OF USING PHOSPHOANTIGENS FOR THE TREATMENT OF DISEASES | INNATE PHARMA (FR) | 2010-05-06 | — | — | WO | disclosed |
| EP-2150258-A2 | IMPROVED METHODS OF USING PHOSPHOANTIGENS TOGETHER WITH INTERLEUKIN-2 FOR THE TREATMENT OF CANCER | Innate Pharma S.A. (FR) | 2010-02-10 | — | — | EP | disclosed |
| WO-2008146167-A2 | IMPROVED METHODS OF USING PHOSPHOANTIGENS TOGETHER WITH INTERLEUKIN-2 FOR THE TREATMENT OF CANCER | INNATE PHARMA S.A. (FR) | 2008-12-04 | — | — | WO | disclosed |
| US-7432253-B2 | Phosphoepoxides, method for making same and uses | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2008-10-07 | — | — | US | disclosed |
| WO-2008051547-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| US-20060287274-A1 | Phosphoepoxides, method for making same and uses | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2006-12-21 | — | — | US | disclosed |
| EP-1720567-A2 | COMPOSITION AND METHOD FOR THE TREATMENT OF CARCINOMA | Innate Pharma (FR) | 2006-11-15 | — | — | EP | disclosed |
| US-7101711-B1 | Phosphoepoxides, method for making same and uses | INSTITUT NATIONAL DE LA SANTA ET DE LA RECHERCHE MEDICALE (FR) | 2006-09-05 | — | — | US | disclosed |
| EP-1569656-A2 | PHOSPHOANTIGENS FOR REGULATING AN IMMUNE RESPONSE | Innate Pharma (FR) | 2005-09-07 | — | — | EP | disclosed |
| WO-2005077411-A2 | COMPOSITION AND METHOD FOR THE TREATMENT OF CARCINOMA | INNATE PHARMA (FR) | 2005-08-25 | — | — | WO | disclosed |
| WO-2004050096-A2 | PHOSPHOANTIGENS FOR REGULATING AN IMMUNE RESPONSE | INNATE PHARMA (FR) | 2004-06-17 | — | — | WO | disclosed |
| EP-1109818-A1 | PHOSPHOEPOXIDES, METHOD FOR MAKING SAME AND USES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000012519-A1 | PHOSPHOEPOXIDES, METHOD FOR MAKING SAME AND USES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287274-A1 | Phosphoepoxides, method for making same and uses | CD4, CCR9, BCL9 | BTN3A1 315/4885MVD 780/4885GGPS1 2332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.